The figure emerged subtly, hidden within a federal health survey. Eight million Americans, approximately the size of New York City’s population, utilized psilocybin over the past year. Not in clinical trials. Not under the supervision of a counselor in an Oregon treatment facility. Just… out and about, in residences and recreational areas, wherever individuals venture when seeking a few hours of a different experience. This statistic, derived from the 2024 National Survey on Drug Use and Health, marks the first nationally representative estimate of its type, and it prompts a question that researchers are only starting to learn how to formulate: what occurs when a drug that functions effectively under controlled circumstances encounters the rather chaotic conditions of everyday life?
For years, the information on psilocybin usage in the US was frustratingly vague. National surveys either grouped it with other hallucinogens or inquired only whether an individual had ever tried it, akin to asking if someone has ever consumed a hot dog and using that to evaluate their overall diet.
The 2024 NSDUH altered that. For the first time, the survey included psilocybin-specific inquiries to over 58,000 participants, enabling Kevin Yang, a resident physician in psychiatry at UC San Diego, along with his colleagues at NYU, to construct a genuinely detailed epidemiological overview. Their findings revealed a 2.8% prevalence in the past year among individuals aged 12 and older. This is a significant portion of the population utilizing a substance that, until very recently, was regarded by federal law as having no accepted medical purpose whatsoever. The landscape has transformed. Oregon initiated regulated psilocybin services in 2023; Colorado followed in 2025. The FDA granted psilocybin breakthrough therapy designation for treatment-resistant depression back in 2018, and for major depressive disorder the subsequent year. The clinical realm has been evolving, and seemingly, so has everyone else.
“Previous surveys only captured lifetime usage, which does little to inform us about current usage patterns,” Yang stated. “A person who experimented with psilocybin once in college ten years ago and someone using it frequently today appear identical in that data. Past-year provides a much more clinically relevant perspective on who is using psilocybin at this moment and what factors are linked to their usage.”
Who Is Actually Using
The demographic distribution is approximately what one might anticipate, if somewhat more pronounced than earlier, less refined estimates suggested. Men significantly outnumbered women (about 64% of past-year users were male). Usage was most prevalent among those aged 18 to 25, and sharply declined after age 50, with individuals over that age showing about one-third the likelihood of usage compared to the 35-49 reference group. White respondents reported notably higher rates than Black or Hispanic respondents. Additionally, having a college education was strongly linked to usage: individuals with some college experience or a degree were about 2 to 2.5 times more likely to have used psilocybin in the past year compared to those without a high school diploma. None of this is particularly surprising in terms of patterns. It reflects the epidemiology of other substance usage, suggesting that access, cultural exposure, and perhaps a certain inclination toward experimentation play significant roles here.
What is more notable is how strongly psilocybin usage correlated with the use of other substances. Cannabis was by far the most robust predictor: individuals who used cannabis in the past year had nearly 14 times the adjusted odds of psilocybin usage compared to non-users. LSD usage was linked to almost 8 times the odds; ketamine with about 6. MDMA, cocaine, prescription stimulant misuse, even alcohol use disorder all demonstrated statistically significant associations. The authors interpret this, quite reasonably, as evidence of a “shared experimentation pattern” rather than psilocybin establishing its own distinct niche. It seems people who use one psychedelic are likely to use several.
The Depression Puzzle
The finding that has garnered the most attention, and which may be the most challenging to interpret, pertains to depression. Individuals who had undergone a major depressive episode in the past year exhibited 37% higher adjusted odds of having used psilocybin. While this may seem modest compared to the cannabis correlation, it carries particular significance given psilocybin’s current development for treatment. The clinical trial literature has been gradually constructing a case for psilocybin-assisted therapy in depression; controlled studies have shown genuinely encouraging results. However, here we observe an association between depression and naturalistic, unsupervised usage, with the direction reversed from what one might naively anticipate.
Earlier epidemiological research, including analyses utilizing older NSDUH data, had indeed found that lifetime psilocybin usage was associated with decreased odds of past-year major